- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02762643
DP-R213 Pharmacokinetics Study
October 31, 2016 updated by: Alvogen Korea
An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetics and Safety of a Fixed Dose Combination of Raloxifen/Cholecalciferol Compared With Coadministration of Raloxifen and Cholecalciferol in Healthy Male Subjects
A randomized, open-label, crossover, Phase I clinical trial to compare the pharmacokinetics of DP-R213 (Raloxifenel and Cholecaliferol fixed dose combinations) in comparison to each component administered alone in healthy male volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- IBW ±20%
- signed the informed consent form prior to the study participation
Exclusion Criteria:
- Clinically significant disease
- Previously donate whole blood within 2 months or component blood within 1 month
- Clinically significant allergic disease
- Taken IP in other trial within 3 months
- An impossible one who participates in clinical trial by investigator's decision including laboratory test result
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RT group
combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
|
Investigational product is prescribed to all of randomized subjects
Investigational product is prescribed to all of randomized subjects
Investigational product is prescribed to all of randomized subjects
|
Experimental: TR group
combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
|
Investigational product is prescribed to all of randomized subjects
Investigational product is prescribed to all of randomized subjects
Investigational product is prescribed to all of randomized subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma concentration versus time curve (AUC)
Time Frame: up to 96 hours post dose
|
up to 96 hours post dose
|
Peak Plasma Concentration (Cmax)
Time Frame: up to 96 hours post dose
|
up to 96 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
April 29, 2016
First Submitted That Met QC Criteria
May 3, 2016
First Posted (Estimate)
May 5, 2016
Study Record Updates
Last Update Posted (Estimate)
November 1, 2016
Last Update Submitted That Met QC Criteria
October 31, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DP-CTR213-I-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on DP-R213
-
Neurolief Ltd.Active, not recruiting
-
Galderma R&DCompletedGlabellar Frown Lines | Canthal LinesUnited States
-
AgonOx, Inc.Providence St Joseph Health; Phio Pharmaceuticals Corp.RecruitingMelanoma | Gynecologic Cancer | Colorectal Cancer | Lung Cancer | HNSCC | Urogenital CancerUnited States
-
D-Pharm Ltd.CompletedStroke | Cerebrovascular Disorders | Brain IschemiaIsrael, Germany
-
ReNeuron LimitedCompletedCerebral Infarction | Hemiparesis | Ischaemic Stroke | Arm ParalysisUnited Kingdom
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingIntraoperative Hemodyamic MonitoringItaly
-
Factor Therapeutics Ltd.Parexel; ARANZ Medical; Almac Clinical Services LLCUnknownPathologic Processes | Cardiovascular Diseases | Vascular Diseases | Skin Diseases | Ulcer | Leg Ulcer | Skin Ulcer | Varicose UlcerUnited States
-
Universidad de ExtremaduraCompletedDistal Pancreatectomy